Glucotrack, Inc. (GCTK): Nasdaq/NYSE listing notice — Glucotrack receives Nasdaq delisting notice for bid price non-compliance; plans to appeal

Glucotrack, Inc.

Nasdaq notified Glucotrack on April 2, 2025 of delisting due to bid price below $1.00 for 30 consecutive business days.
Company intends to request a hearing by April 9, 2025, which will stay the suspension pending Panel decision.
Compliance with Bid Price Rule was previously regained in November 2024; now again non-compliant.
No immediate impact on trading under symbol GCTK; outcome of appeal uncertain.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Glucotrack, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(d)(4)(B)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5815(d)(4)(B)

Exact text from the filing

April 2, 2025, the Company received a letter from Nasdaq (the “Notice”) notifying the Company that as a result of non-compliance with the Bid Price Rule, Nasdaq Qualifications Listing Staff (the “Staff”) has determined to delist the Company’s securities. In accordance with the appeal procedures set forth in the Nasdaq Listing 5800 Series, the Company intends to timely submit a hearing request to the Panel on or before April 9, 2025, which will stay the suspension of the Company’s securities pending the final Panel determination or any extensions they may provide. However, there can be no assur

View on SEC.gov

Browse all listing & compliance notices →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-002802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.